Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 11/20 | 0.76 |
| ▸ | MAOA | P21397 | 8/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.71 |
| ▸ | HPGD | P15428 | 2/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | PPARD | Q03181 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31166914 | 1.00 | MAOB (0.76) | MAOBMAOAALDH1A1CYP3A4HPGD | |
| SCHEMBL4212043 | 0.87 | MAOB (0.58) | MAOBMAOAALDH1A1CYP3A4HPGD | |
| SCHEMBL6763954 | 0.87 | MAOB (1.00) | MAOBMAOAALDH1A1CYP3A4HPGD | |
| SCHEMBL29945833 | 0.86 | MAOB (1.00) | MAOBMAOAMAPTHTTL3MBTL1 | |
| SCHEMBL567416 | 0.86 | MAOB (1.00) | MAOBMAOAMAPTHTTL3MBTL1 | |
| SCHEMBL4216931 | 0.84 | MAOB (0.56) | MAOBMAOAALDH1A1CYP3A4HPGD | |
| Paeonol SCHEMBL29349833 | 0.84 | HPGD (1.00) | MAOBMAOAALDH1A1CYP3A4HPGD | |
| Paeonol SCHEMBL1449478 | 0.84 | HPGD (1.00) | MAOBMAOAALDH1A1CYP3A4HPGD | |
| Paeonol SCHEMBL3710243 | 0.84 | HPGD (1.00) | MAOBMAOAALDH1A1CYP3A4HPGD | |
| SCHEMBL9062621 | 0.83 | MAOB (0.69) | MAOBMAOAALDH1A1CYP3A4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4698520-A1 | RAF-MEK PROTEIN COMPLEX MODULATORS AND METHODS OF USE THEREOF | Gandeeva Therapeutics, Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| WO-2024220708-A1 | RAF-MEK PROTEIN COMPLEX MODULATORS AND METHODS OF USE THEREOF | GANDEEVA THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| US-7732435-B2 | Chromone derivatives useful as antagonists of VR1 receptors | NOVARTIS AG (CH) | 2010-06-08 | — | — | US | disclosed |
| US-7674823-B2 | DNA-PK inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-03-09 | — | — | US | disclosed |
| US-20080312316-A1 | Chromone Derivatives Useful as Antagonists of Vr1 Receptors | CULSHAW ANDREW JAMES | 2008-12-18 | — | — | US | disclosed |
| EP-1963334-A1 | CHROMONE DERIVATIVES USEFUL AS ANTAGONISTS OF VR1 RECEPTORS | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| US-20080114056-A1 | Chromone Derivatives Useful as Vanilloid Antagonists | NOVARTIS AG (CH) | 2008-05-15 | — | — | US | disclosed |
| US-20080114056-A1 | Chromone Derivatives Useful as Vanilloid Antagonists | NOVARTIS AG (CH) | 2008-05-15 | — | — | US | disclosed |
| US-20080114056-A1 | Chromone Derivatives Useful as Vanilloid Antagonists | NOVARTIS AG (CH) | 2008-05-15 | — | — | US | disclosed |
| US-20070238729-A1 | DNA-PK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-10-11 | — | — | US | disclosed |
| WO-2007065888-A1 | CHROMONE DERIVATIVES USEFUL AS ANTAGONISTS OF VR1 RECEPTORS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
| US-7226918-B2 | DNA-PK inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-06-05 | — | — | US | disclosed |
| EP-1756080-A1 | CHROMONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS | Novartis AG (CH) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005121116-A1 | CHROMONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS | NOVARTIS AG (CH) | 2005-12-22 | — | — | WO | disclosed |
| US-20040192687-A1 | Dna-pk inhibitors | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2004-09-30 | — | — | US | disclosed |
| EP-1417196-A1 | DNA-PK INHIBITORS | Cancer Research Technology Limited (GB) | 2004-05-12 | — | — | EP | disclosed |
| WO-2003024949-A1 | DNA-PK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192687-A1 | Dna-pk inhibitors | ATM, CHEK1, XRCC6 | MAOB 3279/4885MAOA 3583/4885ALDH1A1 3564/4885 |
| US-20080114056-A1 | Chromone Derivatives Useful as Vanilloid Antagonists | TRPV1, CHRM3, TRPV3 | MAOB 1622/4885MAOA 1533/4885ALDH1A1 2296/4885 |
| US-20070238729-A1 | DNA-PK INHIBITORS | ATM, CHEK2, CHEK1 | MAOB 2065/4885MAOA 2839/4885ALDH1A1 4037/4885 |
| US-20080312316-A1 | Chromone Derivatives Useful as Antagonists of Vr1 Receptors | VRK1, VRK2, ARRB1 | MAOB 3156/4885MAOA 2558/4885ALDH1A1 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.